Personalizing leukemia care for seniors: a fitness-based treatment strategy put to the test
NCT ID NCT07735208
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether using a comprehensive geriatric assessment to guide treatment selection can reduce side effects and improve outcomes in adults aged 60 and older with newly diagnosed acute myeloid leukemia. Participants are classified as fit, vulnerable, or frail, and receive predefined treatment regimens based on their assessment. The study compares this approach to standard oncologist-directed care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- geriatric assessment-guided treatment regimens
- What this could lead to
- If successful, this approach could help doctors choose safer, more effective treatments for older AML patients based on their overall health, not just age.
- What could go wrong
- This is a mid-stage trial with 120 participants, so results may not apply to all older adults. The benefit of GA-guided treatment over standard care is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of Rochester Medicine
Rochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?